Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.

doi:10.1182/blood.2024024310

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.

Blood - 15 Aug 2024

Othman Jad, Potter Nicola, Ivey Adam, Tazi Yanis, Papaemmanuil Elli, Jovanovic Jelena, Freeman Sylvie D, Gilkes Amanda, Gale Rosemary, Rapoz-D'Silva Tanya, Runglall Manohursingh, Kleeman Michelle, Dhami Pawan, Thomas Ian, Johnson Sean, Canham Joanna, Cavenagh Jamie, Kottaridis Panagiotis, Arnold Claire, Ommen Hans Beier, Overgaard Ulrik Malthe, Dennis Mike, Burnett Alan, Wilhelm-Benartzi Charlotte, Huntly Brian, Russell Nigel H, Dillon Richard

Abstract excerpt

ABSTRACT: Although NPM1-mutated acute myeloid leukemia (AML) carries a generally favorable prognosis, many patients still relapse and die. Previous studies identified several molecular and clinical features associated with poor outcomes; however, only FLT3-internal tandem duplication (ITD) mutation and adverse karyotype are currently used for risk stratification because of inconsistent results and uncertainty...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA (Cytosine-5-)-Methyltransferases

Share to DNA Methyltransferase 3A

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Neoplasm, Residual

Share to Nucleophosmin

Share to WT1 Proteins

Source

Open in PubMed

Identifiers

PMID: 38691678
DOI: 10.1182/blood.2024024310

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.PMID 38691678Read ↗

Prognostic impact of clinico-genetic characteristics and donor types in NPM1-mutated AML undergoing allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.Semantic proximity Read ↗

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.Semantic proximity Read ↗

High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemiaSemantic proximity Read ↗

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.Semantic proximity Read ↗

Prognostic Relevance of NPM1 and FLT3 Mutations in Acute Myeloid Leukaemia, Longterm Follow-Up—A Single Center ExperienceSemantic proximity Read ↗

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.Semantic proximity Read ↗

Prognostication refinement in NPM1-mutated acute myeloid leukemia stratified by FLT3-ITD status with different induction doses of cytarabine.Semantic proximity Read ↗

The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AMLSemantic proximity Read ↗

Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.